ライフサイエンスコーパス: S6 kinase

1 on of its two downstream targets, p21Cip and S6 kinase.

2 activity of its direct downstream target p70 S6 kinase.

3 1 pathway components AMPK, RAGA-1 and RSKS-1/S6 kinase.

4 educed phospho-IRS-1(S302) through AMPKalpha-S6 Kinase.

5 tion depended on activation of p90 ribosomal S6 kinase.

6 uggesting a downstream pathway distinct from S6 kinase.

7 ed phosphorylation of MET, AKT and ribosomal S6 kinase.

8 he protein kinase AKT, protein kinase C, and S6 kinase.

9 tion of the ribosomal regulatory protein p70-S6 kinase.

10 processing is blocked by an inhibitor of p70 S6-kinase.

11 phosphorylates the 70-kDa ribosomal protein S6 kinase 1 (p70S6K1), which subsequently phosphorylates

12 FNlambda activates the p90 ribosomal protein S6 kinase 1 (RSK1) and its downstream effector, initiati

13 dependent kinase 1 target kinases, ribosomal S6 kinase 1 (Rsk1) and Rsk2, produced a striking perturb

14 Ribosomal S6 kinase 1 (RSK1) belongs to a family of proteins with

15 owed that the inactive form of p90 ribosomal S6 kinase 1 (RSK1) interacts with the regulatory subunit

16 In particular, ribosomal S6 kinase 1 (RSK1) silencing increased, whereas RSK2 and

17 ells, interacts with mammalian p90 ribosomal S6 kinase 1 (RSK1), and causes a decrease in NK cell pop

18 ted kinase 2 (ERK2) phosphorylates ribosomal S6 kinase 1 (RSK1), which promotes cellular growth.

19 ase (PKAc) binds to the active p90 ribosomal S6 kinase 1 (RSK1).

20 We provide evidence that S6 kinase 1 (S6K1) Aly/REF-like target (SKAR) is engaged

21 hat curcumin inhibits phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (

22 mTORC1 regulates p70 ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-b

23 ignificantly induced phosphorylation of both S6 kinase 1 (S6K1) and S6 ribosomal protein (S6) in the

24 Phosphorylation of the mTORC1 substrates S6 kinase 1 (S6K1) and S6 was elevated, whereas that of

25 downstream effectors, the ribosomal protein S6 kinase 1 (S6K1) and the translation initiation factor

26 port the identification of ribosomal protein S6 kinase 1 (S6K1) as a novel substrate of PHLPP.

27 complex 1 (mTORC1) and p70 ribosomal protein S6 kinase 1 (S6K1) axis.

28 active and rapamycin-resistant mutant of p70 S6 kinase 1 (S6K1) conferred to resistance to rapamycin.

29 We found that targeting ribosomal protein S6 kinase 1 (S6K1) in Pten-deficient cells suppressed gl

30 ycin complex 1 (mTORC1) and its effector p70 S6 kinase 1 (S6K1) in the extinction of auditory threat

31 Suppression of the ribosomal protein S6 kinase 1 (S6K1) increases healthspan and lifespan in

32 ve shown that loss of ribosomal protein (RP) S6 kinase 1 (S6K1) increases systemic insulin sensitivit

33 S6 kinase 1 (S6K1) is a protein kinase involved in regul

34 The 40S ribosomal S6 kinase 1 (S6K1) is an important regulator of cell gro

35 Aberrant activation of S6 kinase 1 (S6K1) is found in many diseases, including

36 n complex 1 (mTORC1) and its effector kinase S6 kinase 1 (S6K1) is known to trigger multisite seryl p

37 p70 ribosomal protein S6 kinase 1 (S6K1) is regulated by multiple phosphorylat

38 1 (mTORC1)short right arrowribosomal protein S6 kinase 1 (S6K1) pathway decreases tumor suppressor pr

39 Leucine alone stimulated ribosomal protein s6 kinase 1 (S6K1) phosphorylation approximately 280% mo

40 The p70 ribosomal protein S6 kinase 1 (S6K1) plays a key role in cell growth and p

41 Although mTORC1-p70 ribosomal S6 kinase 1 (S6K1) signaling is critical for translation

42 We sought to perturb p70 ribosomal S6 kinase 1 (S6K1), a key translation initiation and elo

43 identified PKD3 to trigger the activation of S6 kinase 1 (S6K1), a main downstream target of the mamm

44 on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiatio

45 tein (4E-BP) and activates ribosomal protein S6 kinase 1 (S6K1), both of which stimulate translation.

46 wnstream of mTORC1 include ribosomal protein S6 kinase 1 (S6K1), eukaryotic translation initiation fa

47 via its downstream target ribosomal protein S6 kinase 1 (S6K1), which directly phosphorylates S1859

48 Overexpression of ribosomal protein S6 kinase 1 (S6k1), which encodes a downstream substrate

49 o the inhibitory effects of rapamycin and an S6 kinase 1 (S6K1)-specific inhibitor on T cell activati

50 promote protein synthesis by activating p70 S6 kinase 1 (S6K1).

51 a on S167 via its effector-the 40S ribosomal S6 kinase 1 (S6K1).

52 ing protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1).

53 of rapamycin complex 1 (mTORC1) known as p70 S6 kinase 1 (S6K1).

54 rate-1 (Tyr-608), Akt (Thr-308 and Ser-473), S6 kinase 1 (Thr-389), eukaryotic initiation factor 4E b

55 phosphorylation (e.g., p70 ribosomal protein S6 kinase 1 [S6K1] and eukaryotic initiation factor 4E b

56 e putative ERK site on IRS1 (Ser(612)) or on S6 kinase 1 activity.

57 ciated with an increase in ribosomal protein S6 kinase 1 and eukaryotic initiation factor 4E-binding

58 itor implicated a role for ribosomal protein S6 kinase 1 in IL-33-induced mTOR-dependent cytokine pro

59 Furthermore, use of a ribosomal protein S6 kinase 1 inhibitor implicated a role for ribosomal pr

60 1-dependent manner in NIH 3T3 cells, whereas S6 kinase 1 is the dominant regulator in hepatocellular

61 orylation of their substrates phosphorylated S6 kinase 1 or phosphorylated S6 ribosomal protein and p

62 the mammalian target of rapamycin complex 1/S6 kinase 1 pathway downstream of nutrient signaling.

63 r signal-regulated kinase 1/2, and ribosomal S6 kinase 1 signal transduction pathways and subsequent

64 ator of mammalian target of rapamycin (mTOR)-S6 kinase 1 signaling.

65 However, activation of the ribosomal S6 kinase 1 via mTOR (P < 0.02), and total upstream bind

66 lysis of divergent signaling through ERK1/2, S6 kinase 1, and 4E binding protein 1 provides insights

67 et of rapamycin complex 1, ribosomal protein S6 kinase 1, and eukaryotic translation initiation facto

68 lular signal-regulated kinase 1/2, ribosomal S6 kinase 1, or cAMP responsive element binding protein

69 d downstream activation of ribosomal protein S6 kinase 1/4E-BP1 pathway.

70 tes (mammalian target of rapamycin complex-1/S6 kinase 1/HIF-1alpha) were detected in LPS-stimulated

71 ing protein 1 (4E-BP1) and ribosomal protein S6 kinase-1 (S6K1), whereas HIF-1alpha degradation remai

72 stream targets Akt and the ribosomal protein S6 kinase-1 (S6K1).

73 is a direct target of the ribosomal protein S6 kinase-1 (S6K1).

74 alpha II (the 70-kDa 40 S ribosomal protein S6 kinase-1 alpha II isoform), and Thr-229 phosphorylati

75 p90 ribosomal S6 kinase 2 (p90RSK2) is important in diverse cellular p

76 We identified ribosomal S6 kinase 2 (RSK2) as the kinase responsible for H2BS32

77 Herein, we found that ribosomal S6 kinase 2 (RSK2) directly phosphorylates histone H2AX

78 l regulatory mechanism whereby p90 ribosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine(2A

79 The ribosomal S6 kinase 2 (RSK2) is a member of the p90 ribosomal S6 k

80 The ribosomal S6 kinase 2 (RSK2) is a well-known serine/threonine kina

81 red that the ERK/MAPK effector p90 ribosomal S6 kinase 2 (RSK2) phosphorylates the 5-HT(2A) receptor

82 Here, we report that p90 ribosomal S6 kinase 2 (RSK2) promotes human HNSCC cell invasion an

83 e previously demonstrated that p90 ribosomal S6 kinase 2 (RSK2) promotes tumor metastasis.

84 otably, we showed that EGF induces ribosomal S6 kinase 2 (RSK2) ubiquitination, and knocking down TRA

85 neurons cultured from mice lacking ribosomal S6 kinase 2 (Rsk2), a model for the Coffin-Lowry syndrom

86 We found that the p90 ribosomal S6 kinase 2 (RSK2)-cAMP response element-binding protein

87 t growth factor 2 (FGF-2) signalling-induced S6 kinase 2 (S6K2) activation is necessary, but the down

88 is study, we evaluated p70 ribosomal protein S6 Kinase 2 (S6K2), a downstream effector of mTORC1, for

89 the MEK inhibitor PD98059, or the ribosomal S6 kinase-2 (RSK-2) inhibitor BI-D1870.

90 The RPS6KA6 gene encodes the p90 ribosomal S6 kinase-4 (RSK4) that is still largely uncharacterized

91 malian target of rapamycin/ribosomal protein S6 kinase, 70 kDa, pathway and thereby stimulate protein

92 malian target of rapamycin/ribosomal protein S6 kinase, 70 kDa, pathway, and the importance of this C

93 Ribosomal protein S6 kinase, 90 kDa, polypeptide 1 (RSK1; official name RP

94 A specific inhibitor of S6 kinase, a downstream target of mTORC1, did not block

95 Phosphorylation of ribosomal S6 kinase, a mammalian target of rapamycin (mTOR) target

96 re hypertrophied, and the phosphorylation of S6 kinase, a target of mammalian target of rapamycin (mT

97 ic target of rapamycin and ribosomal protein S6 kinase A1.

98 Our data reveal a new function for an S6 kinase acting through an AMP kinase in regenerative g

99 We show here that S6 kinase, activated in the liver upon feeding, can phos

100 d in TLR-4-mediated 70-kDa ribosomal protein S6 kinase activation and enhanced TNF-alpha release, whe

101 oxidative stress) that are also positive for S6-kinase activation (a marker associated with aging).

102 ty of glucocorticoids to inhibit Akt and p70 S6 kinase activity and reduced glucocorticoid induction

103 tion leads to reduced mTOR activity, reduced S6 kinase activity, and activation of autophagy to reduc

104 /mammalian target of rapamycin/p70 ribosomal S6 kinase (Akt/mTOR/p70S6K) in the kidney were measured

105 ) phosphorylation of mTOR downstream targets S6 kinase and 4E-binding protein; and (4) formation of e

106 cells based on decreased phosphorylation of S6 kinase and 4E-BP1.

107 transduction to increase phosphorylation of S6 kinase and 4EBP-1.

108 d that UCH-L1 impairs mTORC1 activity toward S6 kinase and 4EBP1 while increasing mTORC2 activity tow

109 by CSPGs selectively inactivated CRMP2, APC, S6 kinase and CREB.

110 We identify central p70 S6 kinase and Erk1/2 pathways as intracellular effectors

111 f raptor and mTOR and the downstream targets S6 kinase and eukaryotic initiation factor 4B.

112 ced phosphorylation of Akt, MAP kinases, and S6 kinase and Fos expression in the absence of Crk and C

113 is, including IFN-induced phosphorylation of S6 kinase and its effector rpS6, as well as phosphorylat

114 ated mTORC1 activity, evidenced by decreased S6 kinase and Lipin1 phosphorylation.

115 AKT/mammalian target of rapamycin/ribosomal S6 kinase and MEK/ERK/RSK pathways because it was resist

116 1/2 and of two downstream targets (ribosomal S6 kinase and mitogen- and stress-activated protein kina

117 ase (AMPK) and upstream of ribosomal protein S6 kinase and mTOR complex 1 (TORC1), by its direct asso

118 Furthermore, ribosomal protein S6 kinase and S6 phosphorylation were increased.

119 ministration simultaneously activated mTORC1/S6 kinase and STAT3 signaling.

120 pS6), suggesting activation of the ribosomal S6 kinases and increased translation.

121 es ordered C-terminal phosphorylation by p70 S6 kinases and p90 ribosomal S6 kinases on four conserve

122 et of rapamycin complex 1 as assessed by p70 S6-kinase and 4E-BP1 phosphorylation.

123 uding mTOR, raptor, rictor, 70-kDa ribosomal S6 kinase, and 4E-binding protein 1 in the mTOR axis by

124 amatically inhibited insulin-stimulated Akt, S6 kinase, and 4E-BP1 phosphorylation but had little eff

125 ed IGF-1R-induced phosphorylation of PRAS40, S6 kinase, and 4EBP-1, indicating inhibition of mTORC1 a

126 ownregulation of germline targets, including S6 kinase, and by the activation of an intestinal transc

127 n-activated protein kinase kinase, ribosomal S6 kinase, and cyclin-dependent kinase 1/2 in combinatio

128 sociated with reduced activation of Akt, p70 S6 kinase, and extracellular regulated kinase signaling

129 owed increased nuclear levels of phospho-p70 S6 kinase, and neurons protected with DRB and flavopirid

130 r signal-regulated kinase, ribosomal protein S6 kinase, and protein kinase D (PKD) that increase cAMP

131 s of p70 S6 protein kinase and p90 ribosomal S6 kinase, and there is good evidence that it plays a po

132 orylation of ERK1/2, CREB, and p90 ribosomal S6 kinase, as well as a decreased level of pore formatio

133 obic motif, on the AGC kinases Akt, PKC, and S6 kinase, as well as an inhibitory site on the kinase M

134 phosphorylation levels of the AKT, MEK, and S6 kinase at concentrations as high as 10 mumol/L.

135 her involving the RPS6KB1 (Ribosomal protein S6 kinase beta-1) were recurrently expressed in a number

136 orylation of its downstream targets mTOR and S6 kinase, but not for Erk1/2 activation.

137 the proteasome (by MG-132) or p90 ribosomal S6 kinases (by BI-D1870) is further increased by knockdo

138 inase, glycogen synthase kinase-3, ribosomal S6 kinase, c-Jun, and cAMP response element binding prot

139 These data illustrate that S6 kinase can modify PGC-1alpha and thus allow molecular

140 We demonstrate that S6 kinases can phosphorylate the extended C-terminal dom

141 as regulated by an ERK1/2- and p90 ribosomal S6 kinase-dependent mechanism, unlike in macrophages in

142 rapamycin (mTOR) hyperactivation, leading to S6-kinase-dependent degradation of p27.

143 for inhibition of Thr-389 phosphorylation on S6 kinases (EC(50) = 2 nM) relative to other inhibitors.

144 The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved

145 , in daf-16/FOXO, sir-2.1, rsks-1 (ribosomal S6 kinase), gcn-2, and aak-2 (AMPK) longevity pathway mu

146 in addition to ERK1/2 and Akt, including p70 S6-kinase, glycogen synthase kinase-3, ribosomal S6 kina

147 RSKs (p90 ribosomal S6 kinases) have emerged as central regulators of cell m

148 ho80p/Pho85p and by the nitrogen-sensing Akt/S6 kinase homolog, Sch9p.

149 ling molecules forkhead box O (FOXO) and p70 S6 kinase in a tissue and blood meal-specific manner.

150 revealed increased phosphorylation of p70S6/S6 kinases in SB-, but not in rhTpo-, treated cells.

151 sphorylation of the S6 kinase RSK (ribosomal S6 kinase) in breast cancer cells.

152 erevisiae homologue of the mammalian Akt and S6 kinase, in DNA damage and genomic instability during

153 Because p70 S6 kinase is known to induce translation of mRNAs contai

154 S6 kinase is the best-characterized downstream effector

155 RSK (p90 ribosomal S6 kinase) is a MAPK-activated protein kinase required f

156 of phosphorylation of ERK-1/2, p90 ribosomal S6 kinase-l and Akt, although phosphorylations occur mor

157 Upon feeding, dietary cholesterol stimulates S6 kinase-mediated phosphorylation of the Boi cytoplasmi

158 target of rapamycin/70-kDa ribosomal protein S6 kinase (mTOR/p70S6K) were not involved.

159 stress and the mammalian target of rapamycin/S6 kinase (mTOR/S6K) pathway.

160 mammalian target of rapamycin complex 1 and S6 kinase (mTORC1--> S6K) attenuates insulin-stimulated

161 rylation by p70 S6 kinases and p90 ribosomal S6 kinases on four conserved Ser residues (Ser-235, Ser-

162 tations in the predicted CeTOR target rsks-1/S6 kinase or in ife-2/eIF4E also reduce protein biosynth

163 > mechanistic target of rapamycin (mTOR) --> S6 kinase or MEK pathways.

164 stream of mTOR, persistent inhibition of p70 S6 kinase or S6K1 can activate Akt via a negative feedba

165 uced decreases in mTOR-regulated phospho-p70 S6 kinase (P-p70) and the p62 protein, as well as increa

166 stern blot analysis of p-mTOR, p70 ribosomal S6 kinase (p-P70S6K), p-S6RP, and p-4EBP1.

167 nd its downstream effector p70/p85 ribosomal S6 kinase (p70/85S6K).

168 ted protein kinases (MAPK)/ribosomal protein S6 kinases (p70 S6K) pathway.

169 ally induced signaling through the ribosomal S6 kinase [p70(389)] is not strain rate sensitive, but i

170 f two mTOR targets, 70-kDa ribosomal protein S6 kinase (p70S6K) and eukaryote initiation factor 4E bi

171 of ERK2, activation of the ribosomal protein S6 kinase (p70S6K) and its downstream target, ribosomal

172 p70 S6 kinase (p70S6K) plays an important role in protein tr

173 ion required phosphorylation of TRIB2 by p70 S6 kinase (p70S6K) via another domain (amino acids 69-85

174 its downstream target, ribosomal protein p70 S6 kinase (p70S6K), and concomitant inhibition of cell g

175 of the downstream pathways of p70 ribosomal S6 kinase (p70S6K), eukaryotic initiation factor 4E-bind

176 S6 is regulated by ERK via the "alternative" S6 kinase p90-ribosomal S6 kinase (RSK), as evidenced by

177 s have identified p90 subfamily of ribosomal S6 kinase (p90RSK) family kinases as key factors for gro

178 se 2 (RSK2) is a member of the p90 ribosomal S6 kinase (p90RSK) family of proteins and plays a critic

179 ine kinase and a member of the p90 ribosomal S6 kinase (p90RSK) family of proteins.

180 (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinas

181 of the known ERK1/2 substrate p90 ribosomal S6 kinase (p90RSK).

182 eport the critical role of the p90 ribosomal S6 kinase (p90RSK)/ERK5 complex in EC dysfunction in dia

183 S6) and the upstream kinase 90-kDa ribosomal S6 kinase (p90S6K).

184 to prevent phosphorylation of the ribosomal S6 kinase partially alleviated the E4orf1 restriction to

185 of the mammalian target of rapamycin (mTOR)/S6 kinase pathway in a PLD- and endocytosis-dependent ma

186 mammalian target of rapamycin complex 1-p70 S6 kinase pathway, a known growth regulatory pathway.

187 f the PI3-kinase/mTOR Complex 1 (mTORC1)/p70 S6-kinase pathway.

188 K3) and mammalian target of rapamycin (mTOR) S6 kinase pathways, protein kinase Czeta (PKCzeta) pathw

189 -3s also reduces the level of phosphorylated S6 kinase, phosphorylated Thor/4E-BP and cyclin E (CycE)

190 The increased S6 kinase phosphorylation in Tec-deficient B cells was d

191 SV treatment also partially blocked mTOR and S6 kinase phosphorylation in TSC1/2-deficient mouse embr

192 not neuroprogenitor cells, ribosomal S6 and S6 kinase phosphorylation increased over time, despite a

193 GDC-0941, targeted the downstream ribosomal S6 kinase phosphorylation to significantly suppress 5-FU

194 rgin stimulated mTORC1 activity (measured as S6 kinase phosphorylation) to a greater extent in wild-t

195 ytes enhanced insulin-stimulated Akt and p70 S6 kinase phosphorylation, as well as GLUT4 translocatio

196 inhibition of the mTORC1 pathway reported by S6 kinase phosphorylation.

197 ted modulation of B7-H2 on GECs involves p70 S6 kinase phosphorylation.

198 or, as measured by reduced ribosomal protein S6 kinase phosphorylation.

199 factor 4E (eIF4E)-eIF4G interactions and p70 S6 kinase polypeptide 1 (S6K1) in reconsolidation.

200 protein kinase 2 (ERK) and ribosomal protein S6 kinase polypeptide 2 (p90RSK).

201 sphorylation of upstream S6 kinase/ribosomal S6 kinase residues.

202 horylation of AMPK and p70 ribosomal protein S6 kinase, respectively) and IL-6/IL-6 receptor signalin

203 mammalian target of rapamycin, p70 ribosomal S6 kinase, ribosomal protein S6, and mitogen activated p

204 ated kinase) and S6K-RPS6 (ribosomal protein S6 kinase-ribosomal protein S6) axes.

205 d required prior phosphorylation of upstream S6 kinase/ribosomal S6 kinase residues.

206 nents diverging, as in the case of ribosomal S6 kinase RPS6KA1.

207 PI3K/mTOR) blockade, including the ribosomal S6 kinases RPS6KA2 (RSK3) and RPS6KA6 (RSK4).

208 Ribosomal protein S6 kinase (RPS6KA3 or RSK2) was the most potent sensitiz

209 o exhibited decreased levels of phospho-Akt, S6 kinase (RPS6KB1), and phosphorylated S6 protein (RPS6

210 ed that WFA activated phosphorylation of the S6 kinase RSK (ribosomal S6 kinase) in breast cancer cel

211 ORF45, mediates sustained ERK-p90 ribosomal S6 kinase (RSK) activation during KSHV lytic replication

212 mall interfering RNA inhibition of ribosomal S6 kinase (RSK) activity induced death of the FGFR1-tran

213 o increased phosphorylation of p90-ribosomal S6 kinase (RSK) and a concomitant activation of ETS-like

214 n to induce cell signaling through ribosomal S6 kinase (RSK) and enhance protein translation.

215 el physiological substrate for p90 ribosomal S6 kinase (RSK) and p70 ribosomal S6 kinase (S6K).

216 While the p90 ribosomal S6 kinase (RSK) family has been implicated in multiple t

217 p90 ribosomal S6 kinase (RSK) family members are effectors for extrace

218 The ribosomal S6 kinase (RSK) family of kinases is a group of extracel

219 ndent protein kinase (PKA) and p90 ribosomal S6 kinase (RSK) in cardiomyocyte apoptosis.

220 tudy evaluated the function of p90 ribosomal S6 kinase (RSK) in the Drosophila circadian system.

221 Ribosomal S6 kinase (RSK) is a key downstream element of the MAPK

222 mediated by either the p90 ribosomal protein S6 kinase (RSK) or p70 S6 kinase (S6K1), in a cell type-

223 lar regulated kinase (ERK) and p90 ribosomal S6 kinase (RSK) proteins, we found several other copurif

224 the phosphorylation of Erk1/2, p90 ribosomal S6 kinase (RSK), and p38 in a temporal order.

225 ia the "alternative" S6 kinase p90-ribosomal S6 kinase (RSK), as evidenced by the site of elevated ph

226 We show here that the ribosomal s6 kinase (Rsk), often elevated in cancers, can suppress

227 causes sustained activation of p90 ribosomal S6 kinase (RSK), which is crucial for KSHV lytic replica

228 ent study has revealed a novel ERK/ribosomal S6 kinase (RSK)-dependent mechanism that regulates DR5 e

229 ing by binding directly to the p90 ribosomal S6 kinase (RSK).

230 gative regulator of IRS-1, the p90 ribosomal S6 kinase (RSK).

231 af-1 phosphorylation by the 90-kDa ribosomal S6 kinase (Rsk).

232 of the MEK kinase (MEKK)1/ERK/p90 ribosomal S6 kinase (RSK)1-dependent C/EBPbeta signaling pathway i

233 The p90 ribosomal S6 kinases (RSK) are implicated in various cellular proc

234 5 is a robust activator of the p90 ribosomal S6 kinases (RSK), and we found that this activity is nec

235 p90 ribosomal S6 kinase (RSK1) is an effector of both Ras/MEK/MAPK and

236 g pathways, we have identified the ribosomal S6 kinase RSKS-1 as a new cell-autonomous inhibitor of a

237 causes sustained activation of p90 ribosomal S6 kinases (RSKs) and extracellular regulated kinase (ER

238 ted herpesvirus interacts with p90 ribosomal S6 kinases (RSKs) and strongly stimulates their kinase a

239 use model of liver-specific knockdown of p70 S6 kinase (S6K) (L-S6K-KD) by systemic delivery of an ad

240 The 40S ribosomal protein S6 kinase (S6K) acts downstream of mTOR, which plays imp

241 urther increased phosphorylation of ribosome S6 kinase (S6K) and BAD (Bcl-2-associated death promoter

242 ATRA suppressed phosphorylation of ribosomal S6 kinase (S6K) and its downstream targets S6 and eIF4B.

243 sion with increased levels of phosphorylated S6 kinase (S6K) and S6 was observed, consistent with con

244 We also demonstrate that S6 kinase (S6K) and serotonin production are involved in

245 hat mammalian target of rapamycin (mTOR) and S6 kinase (S6K) are highly expressed in the undifferenti

246 e investigated the role of ribosomal protein S6 kinase (S6K) at the intersection of nutrition and the

247 Prolonged activation of p70 S6 kinase (S6K) by insulin and nutrients leads to inhibi

248 n Rheb from enhancing the phosphorylation of S6 kinase (S6K) in cells.

249 The 40S ribosomal protein S6 kinase (S6K) is a conserved component of signalling p

250 In this paper, we demonstrate that S6 kinase (S6K) localizes to the presynaptic active zone

251 cell type-specific manner, by either the p70 S6 kinase (S6K) or the p90 ribosomal protein S6K (RSK) a

252 hosphorylation is mediated by either the p70 S6 kinase (S6K) or the p90 ribosomal protein S6K (RSK) i

253 The mammalian target of rapamycin (mTOR) and S6 kinase (S6K) pathway is essential for cell differenti

254 rations activated the PI3K/mTORC2/PKB/mTORC1/S6 kinase (S6K) pathway, but pathophysiologically high a

255 bidopsis TOR activity based on its conserved S6 kinase (S6K) phosphorylation.

256 how that the mechanism for this involves the S6 kinase (S6K) signaling enzyme.

257 tivation of both pathways but also abrogated S6 kinase (S6K) signaling.

258 igration an additional pathway that involves S6 kinase (S6K) through PLD2-Y(296), known to be phospho

259 d oral Mf demonstrated greater inhibition of S6 kinase (S6K), a downstream effector of mTOR complex 1

260 Here, we show that p70 S6 kinase (S6k), acting downstream of the insulin recept

261 iated protein kinases (ROCK1 and ROCK2), p70 S6 kinase (S6K), and mammalian target of rapamycin (mTOR

262 ich syndrome protein (WASp), Grb2, ribosomal S6 kinase (S6K), and Rac2.

263 ion of eIF4E-binding protein (4E-BP) and p70 S6 kinase (S6K), which is important for maintaining tran

264 factor 4E (eIF4E) expression, but inhibited S6 kinase (S6K).

265 ribosomal S6 kinase (RSK) and p70 ribosomal S6 kinase (S6K).

266 induced activation of the mTOR substrate p70 S6 kinase (S6K).

267 strate of p90 ribosomal kinase (RSK) and p70 S6 kinase (S6K).

268 g cascade includes the small GTPase Arf6 and S6 kinase (S6k).

269 ivation of the translation regulatory kinase S6-Kinase (S6K) through modulation of Rictor expression.

270 o, decreased basal Akt and ribosomal protein S6 kinase (S6K1) activation, and decreased transformatio

271 tly PMT induces phosphorylation of ribosomal S6 kinase (S6K1) and its substrate, ribosomal S6 protein

272 we identify a role for the ribosome protein S6 kinase (S6K1) and its upstream regulator mTOR in the

273 gnaling pathway, activation of p70 ribosomal S6 kinase (S6K1) through mTORC1, is also triggered by PK

274 rget of rapamycin (mTOR) downstream effector S6 kinase (S6K1) was confirmed to be activated in immort

275 p70 ribosomal S6 kinase (S6K1), a major substrate of the mammalian tar

276 p90 ribosomal protein S6 kinase (RSK) or p70 S6 kinase (S6K1), in a cell type-specific manner.

277 micking the function of the cellular protein S6 kinase (S6KB1).

278 unction analysis of Drosophila p90 ribosomal S6 kinase (S6KII) or its mammalian homolog RSK has not b

279 Inhibition of mTORC1/S6 kinase signaling by rapamycin induced colocalization

280 ncreased activation of the intracellular Akt/S6 kinase signaling pathway upon BCR and CD40 stimulatio

281 ession as a sensitive reporter of tonic mTOR-S6 kinase signaling through a novel mouse strain, chino,

282 ian target of rapamycin (mTOR)/p70 ribosomal S6 kinase signaling was activated by A53T but not WT alp

283 racellular signal-regulated kinase-ribosomal s6 kinase signaling was downstream of YAP for cell survi

284 nduces autophagy via the suppression of mTOR/S6 kinase signaling.

285 PKD3 potentiates MEK/ERK/RSK (RSK, ribosomal S6 kinase) signaling and significantly enhances cholecys

286 lving Sch9, an homologous kinase to metazoan S6 kinase, targets Maf1 at a subset of PKA sites.

287 subunit of protein kinase A (PKAc), ribosmal S6 kinase that controls RelA Ser 276 phosphorylation.

288 gulates the phosphorylation of p70 ribosomal S6 kinase, the major downstream target of mTOR complex 1

289 rylation of tau can be regulated through p70 S6 kinase, the well characterized immediate downstream t

290 vity (Akt; +113 +/- 31%), p70S6K1 (ribosomal S6 kinase Thr389; 25 +/- 5%), 4E binding protein 1 (4EBP

291 was determined as the phosphorylation of p70 S6 kinase, using Western blotting.

292 unlike in macrophages in which p90 ribosomal S6 kinase was not required.

293 However, phosphorylation of p70 S6 kinase was observed in the liver of all three phenoty

294 Downstream, phosphorylation of S6-kinase was also diminished in both cell lines in a do

295 known Phlpp1 substrates, Akt2, PKC, and p70 S6 kinase, were enhanced in ex vivo cultured Phlpp1(-/-)

296 substrate mTOR, and the mTOR substrate, p70 S6 kinase, were indeed reduced in Hdac3-deficient primar

297 of processing requires the mTORC1 target p70 S6-kinase, whereas induction of mRNA bypasses this enzym

298 unique developmental functions for eIF4E and S6 kinase wherein their activity is specifically uncoupl

299 rol subjects was found for ribosomal protein S6 kinase, which did not change after CBT and did not co

300 reased phosphorylation and activation of p70 S6 kinase, which was inhibited by both DRB and flavopiri